The therapy, developed by PTC Therapeutics, is designed for patients across the severity of spectrum of AADC deficiency. It ...

This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.

An enhanced premium tax credit for Marketplace plans will expire at 2025-end. If Congress doesn't act soon, millions may go ...

PTC Inc (PTC) reports robust financial performance with a 25% increase in free cash flow and announces a $2 billion share repurchase authorization.

Joel Beatty has given his Buy rating due to a combination of factors related to PTC Therapeutics’ promising ... s potential to address an unmet medical need. Beatty acknowledges the strength ...

Good afternoon, ladies and gentlemen, and thank you for standing by, and welcome to today's PTC 2024 fourth-quarter conference call. (Operator Instructions) I would now like to turn the call over to ...

As the medical landscape evolves, ongoing research endeavors focus ... With its distinct characteristics, diagnostic challenges, and evolving treatment modalities, PTC represents a dynamic field of ...

WARREN, N.J., Oct. 1, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of ...